NCT01817153 (HyStOON) is a Phase 2, PHASE3 clinical trial of hydrocortison hemisuccinate in Septic Shock, sponsored by Centre Hospitalier Régional d'Orléans.

Who is sponsoring NCT01817153?

NCT01817153 is sponsored by Centre Hospitalier Régional d'Orléans.

What drugs are being tested in NCT01817153?

Interventions in NCT01817153: hydrocortison hemisuccinate, placebo followed by hydrocortisone hemisuccinate.

What condition does NCT01817153 study?

NCT01817153 studies Septic Shock, Adult.

Is NCT01817153 still recruiting?

NCT01817153 is currently terminated. Last updated 11 February 2020.

Last reviewed 2020-02-11 · How we verify

NCT01817153: HyStOON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.

Terminated Phase 2, PHASE3 Last updated 11 February 2020

What this trial tests

Phase 2, PHASE3 trial testing hydrocortison hemisuccinate in Septic Shock in 10 participants. Terminated before completion.

Timeline

5 November 2013

Primary endpoint
5 November 2019

5 November 2019

Quick facts

Lead sponsor	Centre Hospitalier Régional d'Orléans
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	10
Start date	5 November 2013
Primary completion	5 November 2019
Estimated completion	5 November 2019
Sites	1 location across France

Drugs / interventions tested

hydrocortison hemisuccinate — full drug profile →
placebo followed by hydrocortisone hemisuccinate — full drug profile →

Conditions studied

Septic Shock — all drugs for Septic Shock →
Adult — all drugs for Adult →

Sponsor

Centre Hospitalier Régional d'Orléans

Who can join

18 and older, any sex, with Septic Shock or Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of the study are 1)to examine the immediate (2 hours) and delayed (8 hours) effects of intravenous hydrocortison on macro and microvascular post-ischemic vasoreactivity, in septic shock adult patients; 2) to examine possible correlations between post-ischemic flow-mediated dilation (FMD) of the brachial artery (assessed by ultrasound imaging) and post-ischemic recovery slope of the thenar oxygen saturation (StO2) (assessed by near-infrared spectroscopy).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other Centre Hospitalier Régional d'Orléans trials

Trials by the same sponsor.

NCT07522307 — Psychological Impact of an 80-km Ultra-Endurance Race · recruiting
NCT07522333 — Psychological Impact of an 120-km Ultra-Endurance Race · recruiting
NCT07334964 — Ultrasound-Guided Carpal Tunnel Infiltration: Comparison Between the Manual Method and a Robot-Assisted Method · NA · recruiting
NCT07203807 — Study of the Optimal Number of Repetitions to Investigate the Cerebral Activity by fNIRS During a Voluntary Movement and · completed
NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01817153 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional d'Orléans
Last refreshed: 11 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01817153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing